Abiopharma

🔍 Panacea Innovation Ltd (Executive)

Company: Atara Biotherapeutics, Inc. (ATRA)

Report Date: 2026-01-12

Detailed Transactions and Holdings:

• Sold 80,554 shares of Common Stock at $6.0707 per share (Direct)
  Date: 2026-01-12 | Code: S | equity_swap_involved: false | shares_owned_after: 1,324,446.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-12 | Code: H | nature_of_ownership: See Footnotes | shares_owned_after: 48,736.00 | Footnotes: F2

Footnotes:

• F1: Represents securities held by Panacea Venture Healthcare Fund II, L.P.
• F2: James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. ("Fund II GP") and Panacea Opportunity Fund I GP Company, Ltd. ("Opportunity Fund GP"), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $5.9888 to $6.2838, inclusive. The Reporting Person undertake to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
• F4: Represents securities held by Panacea Opportunity Fund I, L.P.